More encouraging news on the vaccine front. Here is some information we just received from Pfizer:
Pfizer’s COVID-19 vaccine candidate is 95% effective against COVID-19 beginning 28 days after the first dose
We expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021
We plan to submit within days to the FDA for EUA and share data with other regulatory agencies around the glob
Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults over 65 years of age was over 94%
Safety data milestone required by U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) has been achieved
Data demonstrate vaccine was well tolerated across all populations with over 43,000 participants enrolled; no serious safety concerns observed; the only Grade 3 adverse event greater than 2% in frequency was fatigue at 3.8% and headache at 2.0%
Pfizer is confident in its vast experience, expertise and existing cold-chain infrastructure to distribute the vaccine around the world
One of Pfizer’s facilities in the manufacturing and supply chain is located in Andover, Mass.
Comments